The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2024 | Personalized treatment planning for lung cancer with interstitial lung disease
Matthew Hatton, MBChB, MSc, FRCP, FRCR, University of Sheffield, Sheffield, UK, emphasizes the importance of personalized treatment planning for patients with lung cancer and interstitial lung disease (ILD). He highlights key factors such as tumor characteristics, disease stage, histology, performance status, and respiratory function in determining the most appropriate management approach. Prof. Hatton acknowledges the potential benefits of targeted treatments and immunotherapy but cautions that these options may carry a higher risk of exacerbating lung disease in patients with ILD. He also notes the challenge of treating such patients outside the context of clinical trials, as ILD is often an exclusion criterion in trial designs. This interview took place at the BTOG 2024 congress in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
